Participants & Families

The University of Southern Alzheimer’s Disease Research Center has a wide variety of opportunities for volunteers to participate in important research studies designed to discover ways to prevent, treat, and ultimately eradicate Alzheimer’s disease and other dementias. We are looking for a group of diverse volunteers on an ongoing basis to help us as research participants so that we can understand more about memory and aging.

Please call us at (323) 442-7600

Clinical Trials

Donate / Memorial

ALLO Clinical Trial

USC is conducting an early phase clinical trial to evaluate the safety and effect of an experimental drug, allopregnanolone (Allo) on memory. The trial consists of a 16 week study to compare Allo to placebo. The study appointments will consist of cognitive assessment, brain scans, and study related care.

To qualify one must be: Age 55 or older
Diagnosed with: Mild Cognitive Impairment (MCI) or Alzheimer’s Disease (AD)

Qualified participants may receive:
Physical and neurological exams, cognitive testing & MRI scans (brain imaging) Transportation to appointments

Contact: USC Alzheimer Disease Research Center (ADRC)
Attn: Gerson Hernandez (gersonhe@usc.edu)
323-865-ALLO (2556)
323-442-7600

For further information: http://clinicaltrials.gov/show/NCT02221622

Click to view PDF

ADNI 3

The Alzheimer’s Disease Neuroimaging Initiative (ADNI), is now recruiting 1,200 volunteers to join the 800 current participants in its third phase of this multiyear study. ADNI 3 is studying the rate of change in cognition, function, brain structure, and biomarkers among our ADNI volunteers.

To qualify one must be:
• Over age 55 and healthy
ADNI 3 will also be recruiting those with mild memory problems and those who have been diagnosed with mild dementia due to Alzheimer’s disease.
Qualified participants may receive:
• Physical and neurological exams, cognitive testing, MRI scans and PET scans (brain imaging).

For further information, please contact us:
USC Alzheimer Disease Research Center
Nadine Diaz, MSW (ndiaz@usc.edu)
(323) 442 – 7600

A4 Study for healthy older adults

The Anti-Amyloid Treatment in Asymptomatic Alzheimer’s study (the “A4 study” for short) is a clinical study for older individuals (65 to 85 years of age) who may be at risk for memory loss due to Alzheimer’s disease (AD).

The A4 study is investigating a new drug intervention that may reduce the impact of a protein known as “amyloid” or “beta amyloid” forming plaques in the brain. Scientists believe that accumulation of amyloid in the brain may play a key role in the eventual development of AD-related memory loss. The A4 anti-amyloid investigational drug targets amyloid build-up in the brain with the aim of slowing memory loss associated with the development of AD.

Am I eligible?
• The A4 study will enroll 1,000 people between the ages of 65 through 85 with normal thinking and memory function but with evidence of amyloid plaque buildup in the brain.
• Physicians and researchers will use PET amyloid imaging scans to determine whether a potential participant has evidence of elevated amyloid buildup
• Individuals with elevated amyloid on the PET scan will be eligible to become participants in the A4 clinical study.

For further information, please contact us:
USC Alzheimer Disease Research Center
Nadine Diaz, MSW (ndiaz@usc.edu)
(323) 442 – 7600

The ENGAGE Study of Aducanumab for Early Alzheimer’s Disease

This clinical trial evaluates the safety and efficacy of an investigational medication called aducanumab, to determine whether it slows symptoms of Alzheimer’s disease such as memory problems or thinking clearly. Aducanumab is a new type of medication, an antibody that binds to and removes the amyloid fibers that make up the amyloid plaques in the brain that are a part of Alzheimer’s disease. It is believed that removing these fibers will reduce the plaques and improve or slow down the symptoms.

Eligible participants will be between 50 and 85 years old, and experience problems with memory or thinking. Some may have been diagnosed with mild cognitive impairment or mild Alzheimer’s disease previously. Participating in the study will involve visits to USC usually once per month to receive intravenous infusions of aducanumab or an inactive infusion over the course of two years. The trial is being conducted at approximately 150 sites in more than 20 countries in North America, Europe and Asia Pacific.

For more information, please contact us:
USC Alzheimer’s Disease Research Ctr.
Nadine Diaz, MSW at ndiaz@usc.edu
(323) 442-7600

The CREAD Study of Crenezumab for Early Alzheimer’s Disease

The CREAD study is designed to see if an investigational medication called crenezumab can slow the progression of early to mild Alzheimer’s disease. Crenezumab is an antibody that binds to the amyloid in the brain. The amyloid is thought to contribute to the Alzheimer’s disease and the goal of this study is to reduce the amount of amyloid in the brain.

Participants may be able to take part if you are between 50-85 years old, have mild Alzheimer’s disease, or memory problems that may be the early symptoms of Alzheimer’s. Half of the participants enrolled in the study will receive the investigational study medication. The other half will receive a placebo, which contains no active ingredient. The study medications will be given as a 60-minute intravenous infusion every 4 weeks over a period of 2 years. After this time, there may an open-label extension study where all participants receive the investigational study medication.

For more information, please contact us:
USC Alzheimer’s Disease Research Ctr.
Nadine Diaz, MSW at ndiaz@usc.edu
(323) 442-7600

The Healthier Vessels Healthier Brain (HVHB) study

Healthier Vessels, Healthier Brain Study is working to better understand how blood sugar levels and the body’s ability to absorb and use glucose and/or insulin affects capillaries, brain cells, and memory function. People over 60 years of age who have pre-diabetics, diabetics, high blood pressure and/or high cholesterol may be eligible to participate. Please call Lina D’Orazio, Ph.D. (323) 442-7680 or Maria Hernandez (323) 442-6845 for more information.

Brain Research Study (BRS) –The Gift of Knowledge

It has been said that a definitive diagnosis of Alzheimer disease cannot be made until autopsy. This is still true, even though powerful MRI, PET, and CSF markers have greatly improved our ability to make a clinical diagnosis of Alzheimer disease and related disorders. Brain donation can be a priceless gift of knowledge to one’s family and to advances in medical science. The USC ADRC Brain Research Study supports these diagnostic and research studies for participants who have been evaluated and followed over time.

Please call John Danner, LCSW (323) 442-7598 for more information

Completed Treatment Studies